Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Eli Lilly And Co (LLY) vs Lamb Weston Holdings Inc (LW) Price & Performance

Eli Lilly And CoTrade
Lamb Weston Holdings IncTrade

Price performance (Past 24H)

Key statistics

Eli Lilly And Co vs Lamb Weston Holdings Inc — how do they compare? Eli Lilly And Co trades at $1,220.01 (market cap $1.08T), while Lamb Weston Holdings Inc trades at $52.79 (market cap $7.23B). The key difference: Eli Lilly And Co is far larger — about 149.4× Lamb Weston Holdings Inc's market cap, and Lamb Weston Holdings Inc pays the higher dividend (2.89%). Which is the better fit depends on your goals.

LLYLW
Market Cap
$1.08T$7.23B
Sector
HealthConsumer Staples
52-Week High
$1.24K$66.57
52-Week Low
$639.43$38.48
Enterprise Value
$1.13T$11.10B
Dividend Yield
0.57%2.89%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.

Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.

Lamb Weston Holdings Inc

Lamb Weston (LW) trades at $53.10, up 2.49% with a bullish technical signal. The stock shows strong earnings momentum with four consecutive quarterly beats, including Q2 2026 EPS of $0.87 versus $0.62 expected. Valuation metrics include a P/E of 25.28 and P/S of 1.11. Recent news highlights institutional buying and upcoming management participation in investor events, while fundamentals show $6.45B revenue with 4.39% net margin.

LW presents a mixed outlook with solid operational performance offset by margin pressure. The consensus price target of $53.86 offers limited upside, while analyst sentiment leans neutral (63% Hold). Key risks include international headwinds and cost inflation, but North American volume growth and dividend yield of 3.1% provide support. The stock trades near fair value with balanced risk-reward.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY

About Lamb Weston Holdings Inc

Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.

Read more on LW